COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Valuation Ratios Analysis including PE, PB, PS, EV/EBITDA. Analyze if 3349.T stock is undervalued compared to peers/competitors, industry and sector standards or based on Value Investing Principles.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Valuation Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.

Price-to-Earnings Ratio (P/E)

9.89

Increased from previous period

P/E of 9.89 versus zero earnings in Healthcare. Walter Schloss would verify earnings quality.

Price-to-Sales Ratio (P/S)

1.08

Increased from previous period

P/S less than half the Healthcare median of 5.53. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.

Price-to-Book Ratio (P/B)

2.05

Increased from previous period

P/B 1.25-1.5x Healthcare median of 1.64. Guy Spier would scrutinize if premium reflects better asset utilization.

Price-to-Free Cash Flow Ratio

No Data

No Data available this quarter, please select a different quarter.

Price-to-Operating Cash Flow Ratio

No Data

No Data available this quarter, please select a different quarter.

Price-to-Fair Value

2.05

Increased from previous period

Fair value ratio 1.25-1.5x Healthcare median of 1.64. Guy Spier would scrutinize if premium reflects durable advantages.

Earnings Yield

2.53%

Decreased from previous period

Earnings yield exceeding 1.5x Healthcare median of 0.00%. Joel Greenblatt would investigate if high yield reflects hidden value.

Free Cash Flow Yield

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric:

3349.T Valuation Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Price-to-Earnings Ratio (P/E)

9.89

Increased from previous period

P/E of 9.89 versus zero earnings in Healthcare. Walter Schloss would verify earnings quality.

Price-to-Sales Ratio (P/S)

1.08

Increased from previous period

P/S less than half the Healthcare median of 5.53. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.

Price-to-Book Ratio (P/B)

2.05

Increased from previous period

P/B 1.25-1.5x Healthcare median of 1.64. Guy Spier would scrutinize if premium reflects better asset utilization.

Price-to-Free Cash Flow Ratio

No Data

No Data available this quarter, please select a different quarter.

Price-to-Operating Cash Flow Ratio

No Data

No Data available this quarter, please select a different quarter.

Price-to-Fair Value

2.05

Increased from previous period

Fair value ratio 1.25-1.5x Healthcare median of 1.64. Guy Spier would scrutinize if premium reflects durable advantages.

Earnings Yield

2.53%

Decreased from previous period

Earnings yield exceeding 1.5x Healthcare median of 0.00%. Joel Greenblatt would investigate if high yield reflects hidden value.

Free Cash Flow Yield

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric: